Huntington's disease (HD) is an autosomal dominant, progressive neurodegenerative disorder caused by expansion of CAG repeats in the huntingtin gene. Tissue transglutaminase 2 (TG2), a multi-functional enzyme, was found to be increased both in HD patients and in mouse models of the disease. Furthermore, beneficial effects have been reported from the genetic ablation of TG2 in R6/2 and R6/1 mouse lines. To further evaluate the validity of this target for the treatment of HD, we examined the effects of TG2 deletion in two genetic mouse models of HD: R6/2 CAG 240 and zQ175 knock in (KI). Contrary to previous reports, under rigorous experimental conditions we found that TG2 ablation had no effect on either motor or cognitive deficits, or on the weight loss. In addition, under optimal husbandry conditions, TG2 ablation did not extend R6/2 lifespan. Moreover, TG2 deletion did not change the huntingtin aggregate load in cortex or striatum and did not decrease the brain atrophy observed in either mouse line. Finally, no amelioration of the dysregulation of striatal and cortical gene markers was detected. We conclude that TG2 is not a valid therapeutic target for the treatment of HD.
References
[1]
Greenberg CS, Birckbichler PJ, Rice RH (1991) Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5: 3071–3077.
[2]
Im MJ, Riek RP, Graham RM (1990) A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution. J Biol Chem 265: 18952–18960.
[3]
Lai TS, Slaughter TF, Peoples KA, Hettasch JM, Greenberg CS (1998) Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes. Identification of distinct binding sites for Mg-GTP and Mg-ATP. J Biol Chem 273: 1776–1781. doi: 10.1074/jbc.273.3.1776
[4]
Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, et al. (2003) A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373: 793–803. doi: 10.1042/bj20021084
[5]
Mastroberardino PG, Farrace MG, Viti I, Pavone F, Fimia GM, et al. (2006) “Tissue” transglutaminase contributes to the formation of disulphide bridges in proteins of mitochondrial respiratory complexes. Biochim Biophys Acta 1757: 1357–1365. doi: 10.1016/j.bbabio.2006.07.007
[6]
Molberg O, McAdam S, Sollid L (2000) Role of tissue transglutaminase in celiac disease. Journal of Pediatric Gastroenterology & Nutrition 30: 232–240. doi: 10.1097/00005176-200003000-00005
[7]
Mangala L, Mehta K (2005) Tissue Transglutaminase (TG2) in Cancer Biology. In: Mehta K, Eckert R, editors. Transglutaminases: the family of enzymes with diverse functions Basel: Karger. pp. 125–138.
[8]
Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115: 232–245. doi: 10.1016/j.pharmthera.2007.05.003
[9]
Tahri-Joutei A, Pointis G (1989) Developmental changes in arginine vasopressin receptors and testosterone stimulation in Leydig cells. Endocrinology 125: 605–611. doi: 10.1210/endo-125-2-605
[10]
Bates GP, Jones L (2002) Huntington's disease Oxford: Oxford Universtity Press.
[11]
Lesort M, Chun W, Johnson GV, Ferrante RJ (1999) Tissue transglutaminase is increased in Huntington's disease brain. J Neurochem 73: 2018–2027. doi: 10.1046/j.1471-4159.1999.02018.x
[12]
Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJ (2008) Increased levels of gamma-glutamylamines in Huntington disease CSF. J Neurochem 106: 37–44. doi: 10.1111/j.1471-4159.2008.05350.x
[13]
Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, et al. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci U S A 96: 7388–7393. doi: 10.1073/pnas.96.13.7388
[14]
Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22: 8942–8950.
[15]
Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, et al. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8: 143–149. doi: 10.1038/nm0202-143
[16]
Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, et al. (2002) ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9: 873–880. doi: 10.1038/sj.cdd.4401093
[17]
Bailey CD, Johnson GV (2004) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem 92: 83–92. doi: 10.1111/j.1471-4159.2004.02839.x
[18]
Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, et al. (2012) Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. J Med Chem 55: 1021–1046. doi: 10.1021/jm201310y
[19]
Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, et al. (2010) A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen 15: 478–487. doi: 10.1177/1087057110366035
[20]
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493–506. doi: 10.1016/s0092-8674(00)81369-0
[21]
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, et al. (2012) Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175. PLoS One 7: e49838. doi: 10.1371/journal.pone.0049838
[22]
Heikkinen T, Lehtimaki K, Vartiainen N, Puolivali J, Hendricks SJ, et al. (2012) Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One 7: e50717. doi: 10.1371/journal.pone.0050717
[23]
Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, et al. (2001) Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276: 20673–20678. doi: 10.1074/jbc.m010846200
[24]
Menalled L, El-Khodor BF, Patry M, Suarez-Farinas M, Orenstein SJ, et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 35: 319–336. doi: 10.1016/j.nbd.2009.05.007
[25]
Jacobs GH, Fenwick JC, Calderone JB, Deeb SS (1999) Human cone pigment expressed in transgenic mice yields altered vision. J Neurosci 19: 3258–3265.
[26]
Singer J (1998) Using SAS PROC MIXED to fit multilevel models,hierarchical models, and individuals growth models. Journal of Educational and Behavioral Statistics 24: 323–355. doi: 10.3102/10769986023004323
[27]
Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, et al. (2012) Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res 229: 308–319. doi: 10.1016/j.bbr.2011.12.045
[28]
Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, et al. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis 33: 331–341. doi: 10.1016/j.nbd.2008.11.015
[29]
Dragatsis I, Goldowitz D, Del Mar N, Deng YP, Meade CA, et al. (2009) CAG repeat lengths > or = 335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis 33: 315–330. doi: 10.1016/j.nbd.2008.10.009
[30]
Cha JH (2007) Transcriptional signatures in Huntington's disease. Prog Neurobiol 83: 228–248. doi: 10.1016/j.pneurobio.2007.03.004
[31]
Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5: 311–322. doi: 10.1038/nrneurol.2009.54
[32]
Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, et al. (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum Mol Genet 19: 65–78. doi: 10.1093/hmg/ddp467
[33]
Bailey CD, Johnson GV (2006) The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 27: 871–879. doi: 10.1016/j.neurobiolaging.2005.04.001
[34]
Carter RJ, Hunt MJ, Morton AJ (2000) Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov Disord 15: 925–937. doi: 10.1002/1531-8257(200009)15:5<925::aid-mds1025>3.0.co;2-z
[35]
Wood NI, Carta V, Milde S, Skillings EA, McAllister CJ, et al. (2010) Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS One 5: e9077. doi: 10.1371/journal.pone.0009077
[36]
Balci F, Oakeshott S, Shamy JL, El-Khodor BF, Filippov I, et al. (2013) High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's Disease. PLoS Curr 5. doi: 10.1371/currents.hd.124aa0d16753f88215776fba102ceb29
[37]
Chun W, Lesort M, Tucholski J, Ross CA, Johnson GV (2001) Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates. J Cell Biol 153: 25–34. doi: 10.1083/jcb.153.1.25
[38]
Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91: 5355–5358. doi: 10.1073/pnas.91.12.5355
[39]
D'Eletto M, Farrace MG, Rossin F, Strappazzon F, Giacomo GD, et al. (2012) Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins. Cell Death Differ 19: 1228–1238. doi: 10.1038/cdd.2012.2
[40]
Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, et al. (2011) Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet 20: 1937–1951. doi: 10.1093/hmg/ddr075
[41]
Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, et al. (2001) Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Hum Mol Genet 10: 2425–2435. doi: 10.1093/hmg/10.21.2425
[42]
McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, et al. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2: 349–370. doi: 10.1002/emmm.201000084
[43]
Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, et al. (2012) Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease. Exp Neurol 237: 78–89. doi: 10.1016/j.expneurol.2012.05.015
